Key facts
- This page summarizes Eric Lefebvre's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Dec 2022, 20:32.
Eric Lefebvre - 19 Dec 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PLRX
- Reported as of
- 19 Dec 2022
- Net transaction value
- -$207,968
- SEC form
- 4
- Accepted by SEC
- 21 Dec 2022, 20:32:36 UTC
- Prior SEC filing
- 27 Oct 2022
- Next SEC filing
- 25 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Ouimette, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Lefebvre filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 21 Dec 2022.
Change
- Previous filing in this sequence was filed on 27 Oct 2022.
- Current net transaction value: -$207,968.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +21,876
- Change %
- +16%
- Price
- $0.000000
- Shares after
- 155,313
- Date
- 19 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
PLRX
transaction
Common Stock
Sale
- Transaction value
- $207,968
- Shares
- -10,887
- Change %
- -7%
- Price
- $19.10
- Shares after
- 144,426
- Date
- 20 Dec 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,876 shares.
Footnote F2
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4.